All News
Filter News
Found 808,890 articles
-
Phase III RUBY clinical trial demonstrates potential of Jemperli (dostarlimab-gxly) plus chemotherapy to redefine the treatment of primary advanced or recurrent endometrial cancer versus chemotherapy alone
3/27/2023
GSK plc (LSE/NYSE: GSK) today announced interim results from Part 1 of the RUBY/ENGOT-EN-6-NSGO/GOG3031 phase III trial investigating Jemperli (dostarlimab-gxly) plus standard-of-care chemotherapy (carboplatin-paclitaxel) followed by dostarlimab-gxly compared to chemotherapy plus placebo followed by placebo in adult patients with primary advanced or recurrent endometrial cancer.
-
Delcath Systems, Inc. Announces FDA Acceptance of New Drug Application Resubmission of Hepzato Kit with a PDUFA Date of August 14, 2023
3/27/2023
Delcath Systems, Inc. announced that the US Food and Drug Administration (FDA) has accepted Delcath Systems, Inc.'s (Delcath) new drug application resubmission for HEPZATO™ Kit.
-
NeuroSense Therapeutics & Massachusetts General Hospital's NeuroEpigenetics Lab to Collaborate on Elucidating Neurotherapeutic Effects of PrimeC in ALS
3/27/2023
NeuroSense Therapeutics Ltd. today announced it has signed a collaboration agreement with Dr. Ghazaleh Sadri-Vakili, MS, PhD and Massachusetts General Hospital's NeuroEpigenetics Lab to explore the neurotherapeutic effects of its lead combination drug, PrimeC, utilizing a novel in vitro model generated from post-mortem ALS brain tissue (synaptoneurosomes (SNs) system).
-
Barrow Neurological Institute at Phoenix Children's Appoints Neil Friedman, MBChB, as Director
3/27/2023
Barrow Neurological Institute at Phoenix Children's, one of the largest pediatric neuroscience programs in the country, announced the appointment of Neil Friedman, MBChB as director.
-
bioLytical Laboratories Inc. Receives Health Canada Authorization for its INSTI® Multiplex HIV-1/2 Syphilis Antibody Test
3/27/2023
bioLytical Laboratories Inc., a global leader in rapid in-vitro medical diagnostics, announced that it has received Health Canada authorization for its INSTI® Multiplex HIV-1/2 Syphilis Antibody Test, allowing its immediate entry into the Canadian market.
-
Zura Bio Limited Announces Share Redemptions and Lock-up Agreement
3/27/2023
As previously announced on March 21, 2023, Zura Bio Limited (“Zura”) announced the closing of its business combination with JATT Acquisition Corp (“JATT”).
-
Delcath Systems Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
3/27/2023
Delcath Systems, Inc. oday reported business highlights and financial results for the fourth quarter and full year ended December 31, 2022.
-
CANbridge Pharmaceuticals CAN008 Phase 2 Trial for Treatment of Glioblastoma Multiforme (GBM) in China Reaches Full Enrollment
3/27/2023
CANbridge Pharmaceuticals, Inc. (1228.HK) announced that the CAN008 (asunercept) Phase 2 trial for the treatment of glioblastoma multiforme (GBM) in China is fully enrolled, with a total of 117 patients.
-
Olink publishes 2022 annual report
3/27/2023
Olink Holding AB announced that the Annual Report for 2022 is now available on the Company’s website.
-
Cytokinetics Releases Inaugural Corporate Responsibility Report
3/27/2023
Cytokinetics, Incorporated announced the release of its inaugural Corporate Responsibility Report, outlining the Company's commitment to social and environmental responsibility, ethics and governance and patient and community engagement.
-
Midatech Pharma PLC Announces R&D Programme Focused on Leptomeningeal Disease
3/27/2023
Midatech Pharma PLC is pleased to announce a new research programme coded MTD217 focusing on developing new therapeutic options for metastatic cancers with high unmet needs.
-
Meliora Therapeutics Appoints Claudio Chuaqui, Ph.D., as Head of Drug Discovery
3/27/2023
Meliora Therapeutics announced the appointment of Claudio Chuaqui, Ph.D, as Senior Vice President (SVP), Head of Drug Discovery.
-
BioDuro-Sundia Announces Formation of Scientific Advisory Board
3/27/2023
BioDuro-Sundia announced today the establishment of a Discovery Research Scientific Advisory Board (SAB) with the appointment of Andrew Thomas Ph.D. and Zach Sweeney Ph.D. as its members.
-
Merck KGaA, Darmstadt, Germany Strengthens Oncology Franchise by Securing Exclusive Worldwide Rights to Anti PD-L1 Antibody BAVENCIO® (avelumab)
3/27/2023
Merck KGaA, Darmstadt, Germany regains exclusive worldwide rights to develop, manufacture and commercialize BAVENCIO from Pfizer.
-
Imvax Announces First Patient Dosed in Phase 2b Trial of IGV-001 for Glioblastoma
3/27/2023
Imvax, Inc. today announced dosing of the first patient in the company’s randomized, multicenter, double-blind, placebo-controlled Phase 2b clinical trial of IGV-001 in patients with newly diagnosed glioblastoma (ndGBM).
-
OliX Pharmaceuticals Doses First Patient in Clinical Trial for RNAi Therapeutic OLX10212 for Dry and Wet Age-related Macular Degeneration
3/27/2023
OliX Pharmaceuticals, Inc. today announced that the first patient has been successfully dosed in a Phase 1 clinical trial ( NCT05643118 ), evaluating OLX10212, an investigational RNAi therapeutic intended for the treatment of age-related macular degeneration (AMD), including geographic atrophy (GA) and neovascular (nv) AMD.
-
PharmaBlock Opens New R&D Facility in Pennsylvania
3/27/2023
Expanding Capacity to Deliver GMP Projects
-
Biofrontera Inc. Makes Transformative Investment in Its' Dermatology Salesforce
3/27/2023
Biofrontera Inc. today announced that it is executing on the company's stated plans to invest in and meaningfully grow its' salesforce in 2023.
-
Vaxxinity Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Updates
3/27/2023
Vaxxinity, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2022.
-
Todos Medical Begins Trading on the OTC Pink Marketplace
3/27/2023
Todos Medical, Ltd. today announced that its Ordinary shares will begin trading on the OTC Pink marketplace beginning on March 27, 2023 as a result of the Company’s closing bid price falling below $0.001 for 5 consecutive trading days, from March 20, 2023 through March 24, 2023.